Hodgkin's lymphoma, lymphocytic depletion

Summary

Hodgkin’s lymphoma, lymphocytic depletion (MONDO:0004620) is a cancer and 3 clinical trials. Top therapeutic interventions include fludeoxyglucose f 18, ifosfamide, and vinblastine sulfate. A subtype of classic Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• Clinical trials: 3

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.04	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	Hodgkin’s lymphoma, lymphocytic depletion
Mondo ID	MONDO:0004620
Orphanet	98846
DOID	DOID:8628
ICD-11	1729182645
NCIT	C9125
SNOMED CT	118610003
UMLS	C0152267
MedGen	57760
GARD	0019594
Is cancer (heuristic)	yes

Also known as: adult HDLD · adult LDHD · adult lymphocyte depleted classical Hodgkin lymphoma · adult lymphocyte depleted Hodgkin lymphoma · adult lymphocyte depleted Hodgkin’s lymphoma · adult lymphocyte depletion Hodgkin’s disease · Adult lymphocyte-depleted Classic Hodgkin lymphoma · adult lymphocyte-depleted classical Hodgkin lymphoma · classic Hodgkin lymphoma, lymphocyte-depleted type · Hodgkin lymphoma, lymphocyte depletion · Hodgkin’s disease, lymphocytic depletion NOS (morphologic abnormality) · Hodgkin’s disease, lymphocytic depletion, unspecified site, extranodal and solid organ sites · lymphocyte-depleted classical Hodgkin lymphoma

Disease family

This is a subtype of classic Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › classic Hodgkin lymphoma › Hodgkin’s lymphoma, lymphocytic depletion

Related subtypes (3): Hodgkin’s lymphoma, lymphocytic-histiocytic predominance, Hodgkin’s lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03077828	PHASE2	UNKNOWN	Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT03226249	PHASE2	UNKNOWN	PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
NCT03374007	PHASE1	UNKNOWN	Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUDEOXYGLUCOSE F 18	4	1
IFOSFAMIDE	4	1
VINBLASTINE SULFATE	4	1
CHEMBL376464	0	1